The Apprehension/Fear and Somatic Preoccupation/Somatisation Dimensions

  • Roberto Delle ChiaieEmail author
  • Amedeo Minichino


In this chapter, we critically reviewed findings suggesting the existence of two psychopathological dimensions: apprehension/fear and somatic concern/somatisation. The complex interplay between environment, genetics, endocrine and immune systems, and brain circuitries underlying these two dimensions is discussed, with a specific focus on relevance in terms of trans-diagnostic expression. Furthermore, starting with the data presented in Chap. 2, we provide evidence of a clear expression of these two dimensions across traditional diagnostic boundaries, further highlighting the need for a dimensional approach to psychiatric syndromes. Finally, we describe some clinical cases that in our clinical experience might represent an important portrait of a real-word scenario in which these theoretical notions could be applied. Starting with these considerations, an overview of the potential implication for treatment is provided.


Fear Anxiety Stress HPA axis Somatisation Medically unexplained symptoms 


  1. 1.
    Crocq M-AA. history of anxiety: from Hippocrates to DSM. Dialogues Clin Neurosci. 2015;17:319–25.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national comorbidity survey replication. Arch Gen Psychiatry. 2005;62:593.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Steimer T. The biology of fear- and anxiety-related behaviors. Dialogues Clin Neurosci. 2002;4:231–49.PubMedPubMedCentralGoogle Scholar
  4. 4.
    Aldao A, Jazaieri H, Goldin PR, Gross JJ. Adaptive and maladaptive emotion regulation strategies: interactive effects during CBT for social anxiety disorder. J Anxiety Disord. 2014;28:382–9.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Narrow WE, Kuhl EA. Dimensional approaches to psychiatric diagnosis in DSM-5. J Ment Health Policy Econ. 2011;14:197–200.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Parker G, Rosen A, Trauer T, Hadzi-Pavlovic D. Disability associated with mood states and comparator conditions: application of the Life Skills Profile measure of disability. Bipolar Disord. 2007;9:11–5.PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    Kawa S, Giordano J. A brief historicity of the Diagnostic and Statistical Manual of Mental Disorders: issues and implications for the future of psychiatric canon and practice. Philos Ethics Humanit Med. 2012;7:2.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Shorter E. The history of nosology and the rise of the Diagnostic and Statistical Manual of Mental Disorders. Dialogues Clin Neurosci. 2015;17:59–67.PubMedPubMedCentralGoogle Scholar
  9. 9.
    Klein DF. Delineation of two drug-responsive anxiety syndromes. Psychopharmacologia. 1964;5:397–408.PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Regier DA, Kuhl EA, Kupfer DJ. The DSM-5: classification and criteria changes. World Psychiatry. 2013;12:92–8.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Kogan CS, Stein DJ, Maj M, First MB, Emmelkamp PMG, Reed GM. The classification of anxiety and fear-related disorders in the ICD-11. Depress Anxiety. 2016;33:1141–54.PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    Insel T, Cuthbert B, Garvey M, Heinssen R, Pine DS, Quinn K, et al. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry. 2010;167:748–51.CrossRefGoogle Scholar
  13. 13.
    Insel TR. The NIMH Research Domain Criteria (RDoC) project: precision medicine for psychiatry. Am J Psychiatry. 2014;171:395–7.PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    Casey BJ, Craddock N, Cuthbert BN, Hyman SE, Lee FS, Ressler KJ. DSM-5 and RDoC: progress in psychiatry research? Nat Rev Neurosci. 2013;14:810–4.PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Lang PJ, McTeague LM. The anxiety disorder spectrum: fear imagery, physiological reactivity, and differential diagnosis. Anxiety Stress Coping. 2009;22:5–25.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Savage JE, Sawyers C, Roberson-Nay R, Hettema JM. The genetics of anxiety-related negative valence system traits. Am J Med Genet Part B Neuropsychiatr Genet. 2017;174:156–77.CrossRefGoogle Scholar
  17. 17.
    Biondi M, Pasquini M. Dimensional psychopharmacology in somatising patients. Adv Psychosom Med. 2015;2:24–35.CrossRefGoogle Scholar
  18. 18.
    Paulus MP. The breathing conundrum-interoceptive sensitivity and anxiety. Depress Anxiety. 2013;30:315–20.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Nash-Wright J. Dealing with anxiety disorders in the workplace. Prof Case Manag. 2011;16:55–9.PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    Emdin CA, Odutayo A, Wong CX, Tran J, Hsiao AJ, Hunn BHM. Meta-analysis of anxiety as a risk factor for cardiovascular disease. Am J Cardiol. 2016;118(4):511–9. Available from: Scholar
  21. 21.
    Calabrese EJ. Stress biology and hormesis: the Yerkes–Dodson Law in psychology—a special case of the hormesis dose response. Crit Rev Toxicol. 2008;38:453–62.PubMedCrossRefPubMedCentralGoogle Scholar
  22. 22.
    Selye H. Stress in health and disease: Elsevier Science; 1976. p. 1301Google Scholar
  23. 23.
    Zoellner LA, Foa EB. Applying Research Domain Criteria (RDoC) to the study of fear and anxiety: a critical comment. Psychophysiology. 2016;53:332–5.PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Lenze EJ, Wetherell JLA. lifespan view of anxiety disorders. Dialogues Clin Neurosci. 2011;13:381–99.PubMedPubMedCentralGoogle Scholar
  25. 25.
    Hettema JM, Neale MC, Kendler KS. A review and meta-analysis of the genetic epidemiology of anxiety disorders. Am J Psychiatry. 2001;158:1568–78.PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    Smoller JW. Disorders and borders: psychiatric genetics and nosology. Am J Med Genet Part B Neuropsychiatr Genet. 2013;162:559–78.CrossRefGoogle Scholar
  27. 27.
    Smoller JW. The genetics of stress-related disorders: PTSD, depression, and anxiety disorders. Neuropsychopharmacology. 2016;41:297–319.PubMedCrossRefPubMedCentralGoogle Scholar
  28. 28.
    Howe AS, Buttenschøn HN, Bani-Fatemi A, Maron E, Otowa T, Erhardt A, et al. Candidate genes in panic disorder: meta-analyses of 23 common variants in major anxiogenic pathways. Mol Psychiatry. 2016;21:665–79.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Martin EI, Ressler KJ, Binder E, Nemeroff CB. The neurobiology of anxiety disorders: brain imaging, genetics, and psychoneuroendocrinology. Psychiatr Clin North Am. 2009;32:549–75.PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Tovote P, Fadok JP, Lüthi A. Neuronal circuits for fear and anxiety. Nat Rev Neurosci. 2015;16:317–31.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Shin LM, Liberzon I. The neurocircuitry of fear, stress, and anxiety disorders. Neuropsychopharmacology. 2010;35:169–91.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Price JS. Evolutionary aspects of anxiety disorders. Dialogues Clin Neurosci. 2003;5:223–36.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Perusini JN, Fanselow MS. Neurobehavioral perspectives on the distinction between fear and anxiety. Learn Mem. 2015;22:417–25.PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Fanselow MS, Lester LS, Helmstetter FJ. Changes in feeding and foraging patterns as an antipredator defensive strategy: a laboratory simulation using aversive stimulation in a closed economy. J Exp Anal Behav. 1988;50:361–74.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Hoffman AN, Lorson NG, Sanabria F, Foster Olive M, Conrad CD. Chronic stress disrupts fear extinction and enhances amygdala and hippocampal Fos expression in an animal model of post-traumatic stress disorder. Neurobiol Learn Mem. 2014;112:139–47.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Rainnie DG, Mania I, Mascagni F, McDonald AJ. Physiological and morphological characterization of parvalbumin-containing interneurons of the rat basolateral amygdala. J Comp Neurol. 2006;498:142–61.PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    LeDoux JE. Coming to terms with fear. Proc Natl Acad Sci U S A. 2014;111:2871–8.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Anagnostaras SG, Gale GD, Fanselow MS. Hippocampus and contextual fear conditioning: recent controversies and advances. Hippocampus. 2001;11:8–17.PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Stockhorst U, Antov MI. Modulation of fear extinction by stress, stress hormones and estradiol: a review. Front Behav Neurosci. 2015;9:359.PubMedPubMedCentralGoogle Scholar
  40. 40.
    Charney DS. Psychobiological mechanisms of resilience and vulnerability: implications for successful adaptation to extreme stress. Am J Psychiatry. 2004;161:195–216.CrossRefPubMedGoogle Scholar
  41. 41.
    McEwen BS, Gianaros PJ. Central role of the brain in stress and adaptation: links to socioeconomic status, health, and disease. Ann N Y Acad Sci. 2010;1186:190–222.PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Hakamata Y, Komi S, Moriguchi Y, Izawa S, Motomura Y, Sato E, et al. Amygdala-centred functional connectivity affects daily cortisol concentrations: a putative link with anxiety. Sci Rep. 2017;7:8313.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Banks SJ, Eddy KT, Angstadt M, Nathan PJ, Phan KL. Amygdala-frontal connectivity during emotion regulation. Soc Cogn Affect Neurosci. 2007;2:303–12.PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Klumpp H, Keutmann MK, Fitzgerald DA, Shankman SA, Phan KL. Resting state amygdala-prefrontal connectivity predicts symptom change after cognitive behavioral therapy in generalized social anxiety disorder. Biol Mood Anxiety Disord. 2014;4:14.PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    Leweke FM, Giuffrida A, Koethe D, Schreiber D, Nolden BM, Kranaster L, et al. Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use. Schizophr Res. 2007;94:29–36.PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Weisskopf MG, Bauer EP, LeDoux JE, Bauer E, Sweatt J, LeDoux J. L-type voltage-gated calcium channels mediate NMDA-independent associative long-term potentiation at thalamic input synapses to the amygdala. J Neurosci. 1999;19:10512–9.PubMedCrossRefPubMedCentralGoogle Scholar
  47. 47.
    Dell’Osso B, Buoli M, Baldwin DS, Altamura AC. Serotonin norepinephrine reuptake inhibitors (SNRIs) in anxiety disorders: a comprehensive review of their clinical efficacy. Hum Psychopharmacol Clin Exp. 2010;25:17–29.CrossRefGoogle Scholar
  48. 48.
    Verwaerde P, Tran MA, Montastruc JL, Senard JM, Portolan G. Effects of yohimbine, an alpha 2-adrenoceptor antagonist, on experimental neurogenic orthostatic hypotension. Fundam Clin Pharmacol. 1997;11:567–75.PubMedCrossRefPubMedCentralGoogle Scholar
  49. 49.
    Andrade TG, Zangrossi H, Graeff FG. The median raphe nucleus in anxiety revisited. J Psychopharmacol. 2013;27:1107–15.PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    Davis M, Whalen PJ. The amygdala: vigilance and emotion. Mol Psychiatry. 2001;6:13–34.PubMedCrossRefPubMedCentralGoogle Scholar
  51. 51.
    Darling RD, Alzghoul L, Zhang J, Khatri N, Paul IA, Simpson KL, et al. Perinatal citalopram exposure selectively increases locus ceruleus circuit function in male rats. J Neurosci. 2011;31:16709–15.PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Hariri AR, Mattay VS, Tessitore A, Kolachana B, Fera F, Goldman D, et al. Serotonin transporter genetic variation and the response of the human amygdala. Science. 2002;297(5580):400–3.PubMedCrossRefPubMedCentralGoogle Scholar
  53. 53.
    Munafò MR, Brown SM, Hariri AR. Serotonin transporter (5-HTTLPR) genotype and amygdala activation: a meta-analysis. Biol Psychiatry. 2008;63:852–7.PubMedCrossRefPubMedCentralGoogle Scholar
  54. 54.
    Miller R, Wankerl M, Stalder T, Kirschbaum C, Alexander N. The serotonin transporter gene-linked polymorphic region (5-HTTLPR) and cortisol stress reactivity: a meta-analysis. Mol Psychiatry. 2013;18:1018–24.PubMedCrossRefPubMedCentralGoogle Scholar
  55. 55.
    Fang Z, Zhu S, Gillihan SJ, Korczykowski M, Detre JA, Rao H. Serotonin transporter genotype modulates functional connectivity between amygdala and PCC/PCu during mood recovery. Front Hum Neurosci. 2013;7:704.PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Won E, Ham B-J. Imaging genetics studies on monoaminergic genes in major depressive disorder. Prog Neuro-Psychopharmacol Biol Psychiatry. 2016;64:311–9.CrossRefGoogle Scholar
  57. 57.
    Enman NM, Sabban EL, McGonigle P, Van Bockstaele EJ. Targeting the neuropeptide y system in stress-related psychiatric disorders. Neurobiol Stress. 2015;1:33–43.CrossRefPubMedGoogle Scholar
  58. 58.
    Heilig M. The NPY system in stress, anxiety and depression. Neuropeptides. 2004;38:213–24.PubMedCrossRefPubMedCentralGoogle Scholar
  59. 59.
    Eiden LE. Neuropeptide-catecholamine interactions in stress. Adv Pharmacol. 2013;68:399–404.PubMedPubMedCentralCrossRefGoogle Scholar
  60. 60.
    Heim C, Nemeroff CB. The role of childhood trauma in the neurobiology of mood and anxiety disorders: preclinical and clinical studies. Biol Psychiatry. 2001;49:1023–39.PubMedCrossRefPubMedCentralGoogle Scholar
  61. 61.
    Smith SM, Vale WW. The role of the hypothalamic-pituitary-adrenal axis in neuroendocrine responses to stress. Dialogues Clin Neurosci. 2006;8:383–95.PubMedPubMedCentralGoogle Scholar
  62. 62.
    Peeke PM, Chrousos GP. Hypercortisolism and obesity. Ann N Y Acad Sci. 1995;771:665–76.PubMedCrossRefPubMedCentralGoogle Scholar
  63. 63.
    Willette AA, Kapogiannis D. Does the brain shrink as the waist expands? Ageing Res Rev. 2015;20:86–97.PubMedCrossRefPubMedCentralGoogle Scholar
  64. 64.
    Lim L, Chan HN, Chew PH, Chua SM, Ho C, Kwek SK, Lee TS, Loh P, Lum A, Tan YH, Wan YM, Woo M, Yap HL. Ministry of healthclinical practice guidelines: anxiety disorders. Singapore Med J. 2015;56:310–5.PubMedPubMedCentralCrossRefGoogle Scholar
  65. 65.
    Mahadevan J, Sundaresh A, Rajkumar RP, Muthuramalingam A, Menon V, Negi VS, et al. An exploratory study of immune markers in acute and transient psychosis. Asian J Psychiatr. 2017;25:219–23.PubMedCrossRefPubMedCentralGoogle Scholar
  66. 66.
    Ryan MCM, Sharifi N, Condren R, Thakore JH. Evidence of basal pituitary-adrenal overactivity in first episode, drug naïve patients with schizophrenia. Psychoneuroendocrinology. 2004;29:1065–70.PubMedCrossRefPubMedCentralGoogle Scholar
  67. 67.
    Stewart RE, Chambless DL. Cognitive-behavioral therapy for adult anxiety disorders in clinical practice: a meta-analysis of effectiveness studies. J Consult Clin Psychol. 2009;77:595–606.PubMedCrossRefPubMedCentralGoogle Scholar
  68. 68.
    Bandelow B, Seidler-Brandler U, Becker A. Meta-analysis of randomized controlled comparisons of psychopharmacological and psychological treatments for anxiety disorders. World J Biol Psychiatry. 2007;8:175–87.PubMedCrossRefPubMedCentralGoogle Scholar
  69. 69.
    Butler AC, Chapman JE, Forman EM, Beck AT. The empirical status of cognitive-behavioral therapy: a review of meta-analyses. Clin Psychol Rev. 2006;26:17–31.PubMedCrossRefPubMedCentralGoogle Scholar
  70. 70.
    Hoffmann SG, Sawyer AT, Korte KJ, Smits JA. Is it beneficial to add pharmacotherapy to cognitive-behavioral therapy when treating anxiety disorders? A meta-analytic review. Int J Cogn Ther. 2009;2:160–75.CrossRefGoogle Scholar
  71. 71.
    Borgeat F, Stankovic M, Khazaal Y, Rouget BW, Baumann MC, Riquier F, et al. Does the form or the amount of exposure make a difference in the cognitive-behavioral therapy treatment of social phobia? J Nerv Ment Dis. 2009;197:507–13.PubMedCrossRefPubMedCentralGoogle Scholar
  72. 72.
    Bisson J, Andrew M. Psychological treatment of post-traumatic stress disorder (PTSD). Cochrane Database Syst Rev. 2007:CD003388.Google Scholar
  73. 73.
    Pollack MH, Otto MW, Roy-Byrne PP, Coplan JD, Rothbaum BO, Simon NM, et al. Novel treatment approaches for refractory anxiety disorders. Focus. 2008;6:486–95.CrossRefGoogle Scholar
  74. 74.
    Ravindran LN, Stein MB. The pharmacologic treatment of anxiety disorders. J Clin Psychiatry. 2010;71:839–54.PubMedCrossRefPubMedCentralGoogle Scholar
  75. 75.
    Kaizar EE, Greenhouse JB, Seltman H, Kelleher K. Do antidepressants cause suicidality in children? A Bayesian meta-analysis. Clin Trials. 2006;3:73–98.PubMedCrossRefPubMedCentralGoogle Scholar
  76. 76.
    Warden D, Rush AJ, Carmody TJ, Kashner TM, Biggs MM, Crismon ML, et al. Predictors of attrition during one year of depression treatment: a roadmap to personalized intervention. J Psychiatr Pract. 2009;15:113–24.PubMedPubMedCentralCrossRefGoogle Scholar
  77. 77.
    Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC, et al. Antidepressant drug effects and depression severity. JAMA. 2010;303:47–53.PubMedPubMedCentralCrossRefGoogle Scholar
  78. 78.
    Gibbons RD, Hur K, Brown CH, Davis JM, Mann JJ. Benefits from antidepressants: synthesis of 6- week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine. Arch Gen Psychiatry. 2012;21:572–9.Google Scholar
  79. 79.
    Schmitt R, Gazalle FK, Lima MS, de Cunha Ã, Souza J, Kapczinski F. The efficacy of antidepressants for generalized anxiety disorder: a systematic review and meta-analysis. Rev Bras Psiquiatr. 2005;27:18–24.PubMedCrossRefPubMedCentralGoogle Scholar
  80. 80.
    Bakish D, Hooper CL, West DL, Miller C, Blanchard A, Bashir F. Moclobemide and specific serotonin re-uptake inhibitor combination treatment of resistant anxiety and depressive disorders. Hum Psychopharmacol Clin Exp. 1995;10:105–9.CrossRefGoogle Scholar
  81. 81.
    Schutters SIJ, Van Megen HJGM, Van Veen JF, Denys DAJP, Westenberg HGM. Mirtazapine in generalized social anxiety disorder: a randomized, double-blind, placebo-controlled study. Int Clin Psychopharmacol. 2010;25:302–4.PubMedCrossRefPubMedCentralGoogle Scholar
  82. 82.
    Davidson JRT, Weisler RH, Butterfield MI, Casat CD, Connor KM, Barnett S, et al. Mirtazapine vs. placebo in posttraumatic stress disorder: a pilot trial. Biol Psychiatry. 2003;53:188–91.PubMedCrossRefPubMedCentralGoogle Scholar
  83. 83.
    Van Ameringen M, Mancini M, Oakman C, Walker J, Kjernisted J, Chokka P, et al. Nefazodone in the treatment of generalized social phobia: a randomized, placebo-controlled trial. J Clin Psychiatry. 2007;68:288–95.PubMedCrossRefPubMedCentralGoogle Scholar
  84. 84.
    Rickels K, Downing R, Schweizer E, Hassman H. Antidepressants for the treatment of generalized anxiety disorder: a placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry. 1993;50:884–95.PubMedCrossRefPubMedCentralGoogle Scholar
  85. 85.
    Becker ME, Hertzberg MA, Moore SD, Dennis MF, Bukenya DS, Beckham JC. A placebo-controlled trial of bupropion SR in the treatment of chronic posttraumatic stress disorder. J Clin Psychopharmacol. 2007;27:193–7.PubMedCrossRefPubMedCentralGoogle Scholar
  86. 86.
    Simon NM, Otto MW, Worthington JJ, Hoge EA, Thompson EH, LeBeau RT, et al. Next-step strategies for panic disorder refractory to initial pharmacotherapy. J Clin Psychiatry. 2009;70:1563–70.PubMedPubMedCentralCrossRefGoogle Scholar
  87. 87.
    Westra HA, Stewart SH, Conrad BE. Naturalistic manner of benzodiazepine use and cognitive behavioral therapy outcome in panic disorder with agoraphobia. J Anxiety Disord. 2002;16:233–46.PubMedCrossRefPubMedCentralGoogle Scholar
  88. 88.
    Otto MW, McHugh RK, Simon NM, Farach FJ, Worthington JJ, Pollack MH. Efficacy of CBT for benzodiazepine discontinuation in patients with panic disorder: further evaluation. Behav Res Ther. 2010;48:720–7.PubMedPubMedCentralCrossRefGoogle Scholar
  89. 89.
    Feltner DE, Wittchen H-U, Kavoussi R, Brock J, Baldinetti F, Pande AC. Long-term efficacy of pregabalin in generalized anxiety disorder. Int Clin Psychopharmacol. 2008;23:18–28.PubMedCrossRefPubMedCentralGoogle Scholar
  90. 90.
    Feltner DE, Liu-Dumaw M, Schweizer E, Bielski R. Efficacy of pregabalin in generalized social anxiety disorder. Int Clin Psychopharmacol. 2011;26:213–20.PubMedCrossRefPubMedCentralGoogle Scholar
  91. 91.
    Stein DJ, Baldwin DS, Baldinetti F, Mandel F. Efficacy of pregabalin in depressive symptoms associated with generalized anxiety disorder: a pooled analysis of 6 studies. Eur Neuropsychopharmacol. 2008;18:422–30.PubMedCrossRefPubMedCentralGoogle Scholar
  92. 92.
    Furieri FA, Nakamura-Palacios EM. Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2007;68:1691–700.CrossRefPubMedGoogle Scholar
  93. 93.
    Urschel HC, Hanselka LL, Baron M. A controlled trial of flumazenil and gabapentin for initial treatment of methylam-phetamine dependence. J Psychopharmacol. 2011;25:254–62.PubMedCrossRefPubMedCentralGoogle Scholar
  94. 94.
    Houghton KT, Forrest A, Awad A, Atkinson LZ, Stockton S, Harrison PJ, Geddes JR, Cipriani A. Biological rationale and potential clinical use of gabapentin and pregabalin in bipolar disorder, insomnia and anxiety: protocol for a systematic review and meta-analysis. BMJ Open. 2017;7:1–8.CrossRefGoogle Scholar
  95. 95.
    Katon WJ, Walker EA. Medically unexplained symptoms in primary care. J Clin Psychiatry. 1998;59(Suppl 20):15–21.PubMedPubMedCentralGoogle Scholar
  96. 96.
    van Eck van der Sluijs J, Ten Have M, Rijnders C, van Marwijk H, de Graaf R, van der Feltz-Cornelis C. Medically unexplained and explained physical symptoms in the general population: association with prevalent and incident mental disorders. PLoS One. 2015;10:4.CrossRefGoogle Scholar
  97. 97.
    Rosendal M, Olde Hartman TC, Aamland A, van der Horst H, Lucassen P, Budtz-Lilly A, et al. “Medically unexplained” symptoms and symptom disorders in primary care: prognosis-based recognition and classification. BMC Fam Pract. 2017;18:18.PubMedPubMedCentralCrossRefGoogle Scholar
  98. 98.
    Dowrick C. Medically unexplained symptoms in primary care: how can doctors help, not hinder? Ment Health Fam Med. 2010;7:191–2.PubMedPubMedCentralGoogle Scholar
  99. 99.
    Barsky AJ, Peekna HM, Borus JF. Somatic symptom reporting in women and men. J Gen Intern Med. 2001;16:266–75.PubMedPubMedCentralCrossRefGoogle Scholar
  100. 100.
    Harvey SB, Stanton BR, David AS. Conversion disorder: towards a neurobiological understanding. Neuropsychiatr Dis Treat. 2006;2:13–20.PubMedPubMedCentralGoogle Scholar
  101. 101.
    Sirri L, Fava GA. Diagnostic criteria for psychosomatic research and somatic symptom disorders. Int Rev Psychiatry. 2013;25:19–30.PubMedCrossRefPubMedCentralGoogle Scholar
  102. 102.
    Rief W, Barsky AJ. Psychobiological perspectives on somatoform disorders. Psychoneuroendocrinology. 2005;30:996–1002.PubMedCrossRefPubMedCentralGoogle Scholar
  103. 103.
    Liu L, Cohen S, Schulz MS, Waldinger RJ. Sources of somatization: exploring the roles of insecurity in relationships and styles of anger experience and expression. Soc Sci Med. 2011;73:1436–43.PubMedPubMedCentralCrossRefGoogle Scholar
  104. 104.
    Pennebaker JW. Putting stress into words: health, linguistic, and therapeutic implications. Behav Res Ther. 1993;31:539–48.PubMedCrossRefPubMedCentralGoogle Scholar
  105. 105.
    Rief W, Auer C. Is somatization a habituation disorder? Physiological reactivity in somatization syndrome. Psychiatry Res. 2001;101:63–74.PubMedCrossRefPubMedCentralGoogle Scholar
  106. 106.
    Heim C, Ehlert U, Hellhammer DH. The potential role of hypocortisolism in the pathophysiology of stress-related bodily disorders. Psychoneuroendocrinology. 2000;25:1–35.CrossRefGoogle Scholar
  107. 107.
    Rief W, Shaw R, Fichter MM. Elevated levels of psychophysiological arousal and cortisol in patients with somatization syndrome. Psychosom Med. 1998;60:198–203.PubMedCrossRefPubMedCentralGoogle Scholar
  108. 108.
    Rief W, Auer C. Cortisol and somatization. Biol Psychol. 2000;53:13–23.PubMedCrossRefPubMedCentralGoogle Scholar
  109. 109.
    Gaab J, Rohleder N, Nater UM, Ehlert U. Psychological determinants of the cortisol stress response: the role of anticipatory cognitive appraisal. Psychoneuroendocrinology. 2005;30:599–610.PubMedCrossRefPubMedCentralGoogle Scholar
  110. 110.
    Watkins LR, Maier SF. The pain of being sick: implications of immune-to-brain communication for understanding pain. Annu Rev Psychol. 2000;51:29–57.PubMedCrossRefPubMedCentralGoogle Scholar
  111. 111.
    Lekander M, Elofsson S, Neve IM, Hansson LO, Unden AL. Self-rated health is related to levels of circulating cytokines. Psychosom Med. 2004;66:559–63.PubMedCrossRefPubMedCentralGoogle Scholar
  112. 112.
    Dantzer R, Bluthé RM, Layé S, Bret-Dibat JL, Parnet P, Kelley KW. Cytokines and sickness behavior. Ann N Y Acad Sci. 1998;840:586–90.PubMedCrossRefPubMedCentralGoogle Scholar
  113. 113.
    Rief W, Pilger F, Ihle D, Bosmans E, Egyed B, Maes M. Immunological differences between patients with major depression and somatization syndrome. Psychiatry Res. 2001;105:165–74.PubMedCrossRefPubMedCentralGoogle Scholar
  114. 114.
    Hamel E, Currents H. Serotonin and migraine: biology and clinical implications. Cephalalgia. 2007;27:1293–300.PubMedCrossRefPubMedCentralGoogle Scholar
  115. 115.
    Marazziti D, Castrogiovanni P, Rossi A, Rosa C, Ghione S, Di Muro A, et al. Pain threshold is reduced in depression. Int J Neuropsychopharmacol. 1998;1:1.CrossRefGoogle Scholar
  116. 116.
    Schwarz MJ, Späth M, Müller-Bardorff H, Pongratz DE, Bondy B, Ackenheil M. Relationship of substance P, 5-hydroxyindole acetic acid and tryptophan in serum of fibromyalgia patients. Neurosci Lett. 1999;259:196–8.PubMedCrossRefPubMedCentralGoogle Scholar
  117. 117.
    Rief W, Pilger F, Ihle D, Verkerk R, Scharpe S, Maes M. Psychobiological aspects of somatoform disorders: contributions of monoaminergic transmitter systems. Neuropsychobiology. 2004;49:24–9.PubMedCrossRefPubMedCentralGoogle Scholar
  118. 118.
    Mobascher A, Brinkmeyer J, Warbrick T, Musso F, Wittsack HJ, Saleh A, et al. Laser-evoked potential P2 single-trial amplitudes covary with the fMRI BOLD response in the medial pain system and interconnected subcortical structures. Neuroimage. 2009;45:917–26.PubMedCrossRefPubMedCentralGoogle Scholar
  119. 119.
    Jones AKP, Kulkarni B, Derbyshire SWG. Pain mechanisms and their disorders. Br Med Bull. 2003;65:83–93.PubMedCrossRefPubMedCentralGoogle Scholar
  120. 120.
    Boeckle M, Schrimpf M, Liegl G, Pieh C. Neural correlates of somatoform disorders from a meta-analytic perspective on neuroimaging studies. NeuroImage Clin. 2016;11:606–13.PubMedPubMedCentralCrossRefGoogle Scholar
  121. 121.
    Hakala M, Karlsson H, Ruotsalainen U, Koponen S, Bergman J, Stenman H. Severe somatization in women is associated with altered cerebral glucose metabolism. Psychol Med. 2002;3:1379–85.Google Scholar
  122. 122.
    Rauch SL, Phillips KA, Segal E, Makris N, Shin LM, Whalen PJ. A preliminary morphometric magnetic resonance imaging study of regional brain volumes in body dysmorphic disorder. Psychiatry Res. 2003;122:13–9.PubMedCrossRefPubMedCentralGoogle Scholar
  123. 123.
    Mailis-Gagnon A, Giannoylis I, Downar J, Kwan CL, Mikulis DJ, Crawley AP. Altered central somatosensory processing in chronic pain patients with “hysterical” anesthesia. Neurology. 2003;60:1501–7.PubMedCrossRefPubMedCentralGoogle Scholar
  124. 124.
    Vuilleumier P, Chicherio C, Assal F, Schwartz S, Slosman D, Landis T. Functional neuroanatomical correlates of hysterical sensorimotor loss. Brain. 2001;124:1077–90.PubMedCrossRefPubMedCentralGoogle Scholar
  125. 125.
    Bantick SJ, Wise RG, Ploghaus A, Clare S, Smith SM, Tracey I. Imaging how attention modulates pain in humans using functional MRI. Brain. 2002;125:310–9.PubMedCrossRefPubMedCentralGoogle Scholar
  126. 126.
    Eriksen H, Ursin H. Subjective health complaints, sensitization, and sustained cognitive activation (stress). J Psychosom Res. 2004;56:445–8.PubMedCrossRefPubMedCentralGoogle Scholar
  127. 127.
    Ursin H. Sensitization, somatization, and subjective health complaints. Int J Behav Med. 1997;4:105–16.PubMedCrossRefPubMedCentralGoogle Scholar
  128. 128.
    Barsky AJ. Amplification, somatization, and the somatoform disorders. Psychosomatics. 1992;33:28–34.PubMedCrossRefPubMedCentralGoogle Scholar
  129. 129.
    Martin A, Rauh E, Fichter M, Rief W. A one-session treatment for patients suffering from medically unexplained symptoms in primary care: a randomized clinical trial. Psychosomatics. 2007;48:294–303.PubMedCrossRefPubMedCentralGoogle Scholar
  130. 130.
    Smith GR Jr, Monson RA, Ray DC. Psychiatric consultation in somatization disorder. A randomized controlled study. N Engl J Med. 1986;314:1407–13.PubMedCrossRefPubMedCentralGoogle Scholar
  131. 131.
    Kroenke K. Efficacy of treatment for somatoform disorders: a review of randomized controlled trials. Psychosom Med. 2007;69:881–8.PubMedCrossRefPubMedCentralGoogle Scholar
  132. 132.
    Barsky AJ, Ahern DK. Cognitive behavior therapy for hypochondriasis: a randomized controlled trial. JAMA. 2004;291:1464–70.PubMedCrossRefPubMedCentralGoogle Scholar
  133. 133.
    Bleichhardt G, Timmer B, Rief W. Cognitive-behavioural therapy for patients with multiple somatoform symptoms--a randomised controlled trial in tertiary care. J Psychosom Res. 2004;56:449–54.PubMedCrossRefPubMedCentralGoogle Scholar
  134. 134.
    Beltman MW, Voshaar RC, Speckens AE. Cognitive-behavioural therapy for depression in people with a somatic disease: meta-analysis of randomised controlled trials. Br J Psychiatry. 2010;197:11–29.PubMedCrossRefPubMedCentralGoogle Scholar
  135. 135.
    Malins S, Kai J, Atha C, Avery A, Guo B, James M, Patel S, Sampson C, Stubley M, Morriss R. Cognitive behaviour therapy for long-term frequent attenders in primary care: a feasibility case series and treatment development study. Br J Gen Pract. 2016;66:e729–36.PubMedPubMedCentralCrossRefGoogle Scholar
  136. 136.
    Fallon BA. Pharmacotherapy of somatoform disorders. J Psychosom Res. 2004;56:455–60.PubMedCrossRefPubMedCentralGoogle Scholar
  137. 137.
    Fallon BA, Javitch JA, Hollander E, Liebowitz MR. Hypochondriasis and obsessive compulsive disorder: overlaps in diagnosis and treatment. J Clin Psychiatry. 1991;52:457–60.PubMedPubMedCentralGoogle Scholar
  138. 138.
    Kellner R, Fava GA, Lisansky J, Perini GI, Zielezny M. Hypochondriacal fears and beliefs in DSM-III melancholia: changes with amitriptyline. J Affect Disord. 1986;10:21–6.PubMedCrossRefPubMedCentralGoogle Scholar
  139. 139.
    Noyes R, Reich J, Clancy J, O’Gorman TW. Reduction in hypochondriasis with treatment of panic disorder. Br J Psychiatry. 1986;149:631–5.PubMedCrossRefPubMedCentralGoogle Scholar
  140. 140.
    Kamlana SH, Gray P. Fear of AIDS (letter). Br J Psychiatry. 1988;15:1291.Google Scholar
  141. 141.
    Stone AB. Treatment of hypochondriasis with clomipramine (letter). J Clin Psychiatry. 1993;54:5.Google Scholar
  142. 142.
    Fallon BA, Schneier FR, Marshall R, Campeas R, Vermes D, Goetz D, Liebowitz MR. The pharmacotherapy of hypochondriasis. Psychopharmacol Bull. 1996;32:607–11.PubMedPubMedCentralGoogle Scholar
  143. 143.
    Viswanathan R, Paradis C. Treatment of cancer phobia with fluoxetine. Am J Psychiatry. 1991;148:1090.PubMedPubMedCentralGoogle Scholar
  144. 144.
    Fallon BA, Feinstein S. Hypochondriasis. In: Phillips KA, editor. Somatoform and fictius disorders. Washington, DC: America Psychiatric Publishing; 2001.Google Scholar
  145. 145.
    Fallon BA, Liebowitz MR, Salomon E, Schneier FR, Jusino C, Holander E, Klein DF. Fluoxetine for hypochondriacal patients without major depression. J Clin Psychopharmacol. 1993;13:438–41.PubMedCrossRefPubMedCentralGoogle Scholar
  146. 146.
    Fallon BA, Qureshi AI, Schneier FR, Sanchez-Lacay A, Vermes D, Feinstein R, Connelly J, Liebowitz MR. An open trial of fluvoxamine for hypochondriasis. Psychosomatics. 2003;44:298–303.PubMedCrossRefPubMedCentralGoogle Scholar
  147. 147.
    Oosterbaan DV, van Balkom AJ, van Boijen CA, De Metji TG, van Dick R. An open study of paroxetine in hypochondriasis. Prog Neuropsychopharmacol Biol Psychiatry. 2001;25:1023–33.PubMedCrossRefPubMedCentralGoogle Scholar
  148. 148.
    Kjernisted KD, Enns MW, Lander M. An open clinical trial of nefazodone in hypochondriasis. Psychosomatics. 2002;43:290–4.PubMedCrossRefPubMedCentralGoogle Scholar
  149. 149.
    Wesner RB, Noyes R. Imipramine: an effective treatment for illness phobia. J Affect Disord. 1992;22:43–8.CrossRefGoogle Scholar
  150. 150.
    Fallon BA. Pharmacotherapy of hypochondriasis. Marburg: International Congress on Somatoform Disorders; 2002.Google Scholar
  151. 151.
    Escobar JR, Rubio-Stipec R, Canino G, Karno M. Somatic Symptom Index (SSI): a new and abridged somatization construct. J Nerv Ment Dis. 1989;177:140–6.PubMedCrossRefPubMedCentralGoogle Scholar
  152. 152.
    Noyes R, Happel R, Muller B, Holt CS, Kathol RG, Sieren L, Amos J. Fluvoxamine for somatoform disorders: an open trial. Gen Hosp Psychiatry. 1998;20:339–44.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Human NeurosciencesSapienza University of RomeRomeItaly

Personalised recommendations